Science 37 Holdings, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statement of Cash Flows (Statement)

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Jun 30, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Interest earned on marketable securities held in Trust Account
Depreciation and amortization
Non-cash lease expense related to operating lease right-of-use assets
Stock-based compensation
(Gain) loss on change in fair value of earn-out liability
Loss on long-lived asset impairment
Gain on foreign currency exchange rates
Provision for doubtful accounts
Loss on disposal of fixed assets
Changes in operating assets and liabilities:
Prepaid expenses
Accounts payable and accrued expenses
Accounts receivable and unbilled services
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses and other current liabilities
Deferred revenue
Operating lease liabilities
Other, net
Net cash used in operating activities
Cash flows from investing activities:
Investment of cash into Trust Account
Payments related to capitalized software development costs
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from Series D-1 financing, net of issuance costs
Repurchase of common stock
Proceeds from warrant exercises
PIPE shares issuance, net of transaction costs
Proceeds from sale of Units, net of underwriting discounts paid
Proceeds from sale of Private Placement Warrants
Proceeds from promissory note - related party
Repayment of promissory note - related party
Payment of offering costs
Merger shares issuance, net of transaction costs
Proceeds from stock option exercises
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Initial classification of common stock subject to possible redemption
Change in value of Class A common stock subject to possible redemption
Supplemental disclosures of non-cash activities
Balance in accounts payable and accrued expenses and other current liabilities, and capitalized stock-based compensation related to capitalized software and fixed asset additions
Right-of-use asset obtained in exchange for operating lease liabilities
Conversion of preferred stock into common stock
Earn-out shares

Comments